Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer

The efficacy and safety of immune checkpoint inhibitor (ICI) monotherapy in elderly patients with non‐small cell lung cancer (NSCLC) remain unclear, especially in patients older than 80 years. We retrospectively reviewed the records of 10 patients older than 80 years with NSCLCs treated by ICIs. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Chikaishi, Yasuhiro, Inoue, Masaaki, Kusanagi, Kasumi, Honda, Yohei, Yoshida, Junichi, Tanaka, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954839/
https://www.ncbi.nlm.nih.gov/pubmed/33738379
http://dx.doi.org/10.1002/agm2.12147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954839/
https://www.ncbi.nlm.nih.gov/pubmed/33738379
http://dx.doi.org/10.1002/agm2.12147

Ejemplares similares